CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE). NTLA-2002 is a wholly owned investigational in vivo CRISPR-based therapy in development as a single-dose treatment for this potentially life-threatening disease. Inte ...

Intellia Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - NTLA ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Investors to Learn More About the Investigation ...

Group 1 - The article discusses an active investigation regarding Intellia Therapeutics, Inc. and encourages investors who lost money to contact Levi & Korsinsky [1] Group 2 - The focus is on potential financial losses incurred by investors in Intellia Therapeutics, Inc. due to unspecified issues leading to the investigation [1]

Intellia Therapeutics, Inc. (NTLA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation ...

Intellia Therapeutics, Inc. (NTLA) lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization.Intellia is a clinical-stage gene editing company focused on developing innovative CRISPR-based therapies. As part of the recently announced portfolio reorganization, NTLA is planning to prioritize the development of its late-stage programs — NTLA-2002 and nexiguran ziclumeran (nex-z). The company will also reduce its workforce by 27% in 2025.NTLA Underperforms Industr ...

Recently, I published an article describing why I believe Crispr Therapeutics ( CRSP ) is on a good track to achieve profitability by 2028 or earlier, despite the slow Casgevy rollout and the marketOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to asses ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Intellia Therapeutics, Inc. (NTLA) and Encourages Stockholders to Learn More About the Investigation ...

Core Viewpoint - Intellia Therapeutics, Inc. is currently under investigation, which may impact its operations and investor confidence [1] Company Summary - The investigation is being conducted by Levi & Korsinsky, a law firm, indicating potential legal issues that could affect the company's reputation and stock performance [1] - The investigation may relate to the company's compliance with regulations or disclosures, which is critical for maintaining investor trust and market position [1] Industry Summary - The ongoing investigation highlights the importance of regulatory compliance in the biotechnology sector, where companies are often scrutinized for their research and development practices [1] - Legal challenges in the biotech industry can lead to significant volatility in stock prices, affecting overall market sentiment towards similar companies [1]

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLA ...